Key Stats for IQVIA Stock
- This Week Performance: -6.6%
- 52-Week Range: $134.7 to $247.1
- Current Price: $162.9
What Happened?
What Wall Street initially punished as a guidance miss has become the entry point for a reappraisal thesis, as IQVIA — the world’s largest healthcare data and clinical research organization — trades at $162.93 against a median analyst target of $262.50, a 61.1% gap, while its R&DS backlog hit a record $32.7 billion on February 5.
On February 5, CEO Ari Bousbib defended IQVIA’s AI strategy on the Q4 2025 earnings call after shares fell over 8% to $186.56, as the company’s 2026 adjusted EPS guidance of $12.55 to $12.85 missed the $12.95 analyst consensus due to approximately $80 million in higher interest expenses from 2025 financing activity.
Beneath the guidance noise, IQVIA’s core clinical trial services business — which manages drug development programs for pharma and biotech clients globally — delivered Q4 revenue of $4.364 billion, beating the $4.240 billion consensus by 2.9%, while full-year free cash flow reached $2.051 billion, representing approximately 99% of adjusted net income.
CFO Mike Fedock stated at the Barclays 28th Annual Global Healthcare Conference on March 12 that “AI is a net positive to IQVIA on both in terms of revenue and margin expansion over time,” and disclosed that 19 of the top 20 pharma companies already operate AI agents IQVIA built inside their own workflows.
With over 150 agents deployed across 30 use cases, a roadmap targeting 500 agents by 2027, the February 25 acquisition of five Charles River drug discovery sites for approximately $145 million, and 2026 revenue guidance of $17.15 billion to $17.35 billion, IQVIA’s convergence of proprietary data, clinical scale, and agentic AI positions it to compound its lead over rivals as the industry’s outsourcing cycle reaccelerates.
Wall Street’s Take on IQVIA Stock
The AI-driven selloff that pushed IQV to $162.93 created a disconnect between sentiment and fundamentals, as IQVIA’s record $32.7 billion R&DS backlog — clinical trial work already contracted and in progress — de-risks the 2026 revenue guide of $17.15 billion to $17.35 billion almost entirely from existing committed work.
IQVIA’s normalized EPS compounds from $11.92 in 2025 to an estimated $20.26 by December 2030, a 10.9% annual growth rate under the TIKR mid-case, supported by EBITDA margins expanding from 23.2% today to 24.1% as the 150-agent AI platform scales across both clinical and commercial workflows and drives operating leverage.
Seventeen of 25 covering analysts rate IQV a buy and three as outperform, with a mean price target of $236.19 implying 45.0% upside from the March 12 close of $162.93, reflecting confidence that the AI selloff overshot and that the record backlog and accelerating biotech funding restore the growth trajectory.
The analyst target range spans $200.00 on the low end to $287.00 on the high end, where the bear case hinges on whether higher interest expenses — approximately $80 million above 2025 levels — persistently compress EPS growth, while the bull case prices in full monetization of the DaaS Plus platform and the five newly acquired Charles River discovery sites.
What Does the Valuation Model Say?
The TIKR mid-case target of $283.85 prices in a revenue CAGR of 6.8% through December 2030 and net income margins expanding to 13.9%. Those inputs are grounded directly in IQVIA’s 2026 Commercial Solutions guidance of $7.2 billion to $7.3 billion and the company’s stated roadmap to deploy over 500 AI agents by 2027.
The market prices IQV at roughly 12.8x forward earnings today versus its 5-year average of 19.8x, implying a 35% multiple discount despite a business whose proprietary data assets and $32.7 billion backlog make revenue far more visible than in a typical services firm.
Nineteen of the top 20 pharma companies already operate IQVIA-built agents inside their own workflows, confirming that AI adoption is generating client lock-in, not displacement, and directly supporting the TIKR model’s assumption of accelerating commercial revenue growth.
CFO Mike Fedock disclosed at the March 12 Barclays conference that IQVIA internally benchmarked a competing AI model against its own proprietary dataset and the outside model identified only 3 of the top 10 key opinion leaders correctly, demonstrating the data moat the TIKR model prices as durable.
The key risk is interest expense: the approximately $80 million year-over-year increase in net interest costs — driven by 2025 senior note issuance and expected 2026 refinancing — directly compresses EPS growth and breaks the model’s EPS CAGR assumption if refinancing rates come in above current guidance.
The Q1 2026 earnings call is the first confirmation point, where adjusted EPS guidance of $2.77 to $2.87 and a book-to-bill ratio above 1.15 would signal that the demand recovery and margin trajectory the TIKR mid-case requires are both tracking on schedule.
Should You Invest in IQVIA Holdings Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IQV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IQVIA Holdings Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IQV stock on TIKR for Free →
